ERBB2 and breast carcinoma: First, trastuzumab, combined with first-line CT, obtained approval for metastatic HER2+ breast cancer [112]; then, after showing efficacy and safety in early breast cancer, it also became a conventional neo-adjuvant or adjuvant treatment in association with different anti-HER2 therapies and/or CT [9,30,113].